Customized Therapeutics is a biopharmaceutical company engaged in the development and commercialization of products and services that enable patients to get the Right Treatment at the Right Time, All the Time. Our objective is to identify genetic and genomic aberrations associated with patient's response to treatment, risk of disease recurrence and overall survival. The developed products will help physicians identify the best course of treatment that improves the survival rates and Quality of Life of cancer patients.

Our lead product, CT-VALA is a treatment responsiveness indicator assay for breast cancer patients. The assay will pre-select the minority of patients who are expected to respond to therapy and spare the majority of patients the agony and expense of therapy to which they are unlikely to respond. There are currently no products that identify the likelihood of response to chemotherapy in breast cancer and CT-VALA will be a First to Market product. Our diagnostic pipeline also includes similar assays for Prostate and Ovarian cancers.

Customized Therapeutics is also building a pipeline of novel therapeutics, and drug delivery systems through in-house development and in-licensing of technologies with high clinical value. These products cater to the unmet need for improved and targeted therapies with low system toxicities and high efficacy. The company utilizes innovative clinical trial designs and a streamlined approach to reduce the product development time from lab to market.

Investors

The company is currently seeking investors to fund new product development activities and expansion of facilities. Please contact us at 626.296.6464 for additional details.